Less investment but more value for Singapore biomedical sector last year
This article was originally published in Scrip
While Singapore saw a sharp fall in investment commitments in the biomedical manufacturing sector last year, these have shifted to operations and products that are expected to add more value to the economy in the future, the latest figures from the island state's Economic Development Board (EDB) show.
You may also be interested in...
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Japanese major builds presence in novel device technology beyond its conventional therapeutics as looks towards a more holistic future of care.
Join the Asia content team for a wide-ranging overview and analysis of developments and trends in the region, including coronavirus vaccines in China, Korean developments in NASH, digital health shifts, Indian corporate performance and Japanese deal trends.